NTLA
Price
$6.89
Change
-$0.41 (-5.62%)
Updated
Apr 3 closing price
Capitalization
712.2M
27 days until earnings call
SLDB
Price
$3.40
Change
-$0.29 (-7.86%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
263.86M
Ad is loading...

NTLA vs SLDB

Header iconNTLA vs SLDB Comparison
Open Charts NTLA vs SLDBBanner chart's image
Intellia Therapeutics
Price$6.89
Change-$0.41 (-5.62%)
Volume$3.89M
Capitalization712.2M
Solid Biosciences
Price$3.40
Change-$0.29 (-7.86%)
Volume$4.6K
Capitalization263.86M
NTLA vs SLDB Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. SLDB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and SLDB is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (NTLA: $6.89 vs. SLDB: $3.40)
Brand notoriety: NTLA and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 114% vs. SLDB: 25%
Market capitalization -- NTLA: $712.2M vs. SLDB: $263.86M
NTLA [@Biotechnology] is valued at $712.2M. SLDB’s [@Biotechnology] market capitalization is $263.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileSLDB’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 5 bearish.
  • SLDB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than SLDB.

Price Growth

NTLA (@Biotechnology) experienced а -17.98% price change this week, while SLDB (@Biotechnology) price change was -22.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

NTLA is expected to report earnings on May 01, 2025.

SLDB is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($712M) has a higher market cap than SLDB($264M). SLDB YTD gains are higher at: -14.875 vs. NTLA (-40.909). SLDB has higher annual earnings (EBITDA): -121.9M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. SLDB (149M). SLDB has less debt than NTLA: SLDB (24.2M) vs NTLA (210M). NTLA has higher revenues than SLDB: NTLA (57.9M) vs SLDB (0).
NTLASLDBNTLA / SLDB
Capitalization712M264M270%
EBITDA-523.98M-121.9M430%
Gain YTD-40.909-14.875275%
P/E RatioN/AN/A-
Revenue57.9M0-
Total Cash602M149M404%
Total Debt210M24.2M868%
FUNDAMENTALS RATINGS
NTLA vs SLDB: Fundamental Ratings
NTLA
SLDB
OUTLOOK RATING
1..100
6056
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9593
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (25) in the Biotechnology industry is in the same range as SLDB (37). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLDB (100). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as SLDB (98). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (93) in the Biotechnology industry is in the same range as NTLA (95). This means that SLDB’s stock grew similarly to NTLA’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that SLDB’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLASLDB
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 23 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVRSX28.71N/A
N/A
VY® CBRE Real Estate S
GLOSX19.41N/A
N/A
Victory Pioneer Global Equity A
ICEIX22.26N/A
N/A
Macquarie International Core Eq I
LAFSX18.79N/A
N/A
Lord Abbett Affiliated R4
GMNAX10.51N/A
N/A
Gabelli Global Mini Mites A

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-7.72%
EDIT - SLDB
43%
Loosely correlated
-4.66%
ALLO - SLDB
42%
Loosely correlated
-3.82%
BEAM - SLDB
42%
Loosely correlated
-10.93%
KRYS - SLDB
42%
Loosely correlated
-1.58%
NTLA - SLDB
41%
Loosely correlated
-5.75%
More